Catalio Capital closes over $400M Fund IV
In Brief Venture capital firm Catalio Capital Management announced today the closing of its more than $400 million Fund IV, as first reported by Bloomberg. The fund will continue the firm’s thesis of backing healthcare and biotechnology companies. The firm was founded in 2020 and has made more than 100 investments, according to PitchBook. Catalio’s Fund IV, in particular, has backed 16 companies already, including the diagnostics company PinkDx and the drug discovery company Superluminal Medic